Consent given pursuant to Sections 14 and 14A for the importation and supply of the therapeutic goods specified by Astellas Pharma Australia

Overview

The Therapeutic Goods Act 1989 is a pivotal piece of legislation in Australia that was enacted to regulate therapeutic goods, including medicines, medical devices, and other health-related products. The Act was introduced to address the need for a comprehensive legal framework governing the safety, efficacy, and quality of therapeutic goods, thereby protecting public health. This legislation is enacted by the Parliament of Australia and aims to ensure that therapeutic goods available in the Australian market meet certain standards to safeguard consumers. The Act provides mechanisms for the regulation of therapeutic goods through the Therapeutic Goods Administration (TGA), which is responsible for assessing and monitoring these products to ensure compliance with the legislative requirements. On 9 April 2015, the delegate of the Secretary of the Department of Health granted consent under Section 14 and 14A of the Therapeutic Goods Act 1989 for the importation and supply of tacrolimus products by Astellas Pharma Australia Pty Ltd. This consent allowed for the continued supply of tacrolimus products with labels that did not fully conform to the Therapeutic Goods Order 69, specifically concerning the inclusion of previous sponsor details. The consent, effective from 9 April 2015 until 31 March 2016, was subject to conditions ensuring that the labels remained unchanged and that all correspondence was redirected to the current sponsor, Astellas Pharma. This action highlights the Act's flexibility in allowing for specific exceptions to regulatory requirements to ensure the continued availability of essential medicines while maintaining overall regulatory standards.

Scope and Application

The Therapeutic Goods Act 1989, specifically in sections 14 and 14A, governs the regulation of therapeutic goods within Australia, with the Therapeutic Goods Administration (TGA) under the Department of Health acting as the regulatory body. The Act applies to both individuals and entities involved in the importation, supply, and manufacture of therapeutic goods, encompassing a wide range of products including medicines, medical devices, and blood products. The jurisdictional reach of the Act is national, ensuring a consistent regulatory framework across all Australian states and territories. The Act includes provisions for exemptions and exclusions, particularly through Therapeutic Goods Orders which can tailor regulations to specific goods or classes of goods. The application of the Act can be further extended or restricted through subordinate instruments, such as the Therapeutic Goods Regulations 1990, which provide detailed rules and standards for compliance. In this particular case, the Act was applied to allow the importation and supply of specific tacrolimus products by Astellas Pharma Australia Pty Ltd, despite the products not fully conforming to the labelling requirements stipulated in Therapeutic Goods Order 69. The consent granted under the Act specifies conditions to ensure the safety and quality of the therapeutic goods, such as maintaining the existing labels and redirecting correspondence to the current sponsor. This case illustrates the Act's flexibility in addressing specific circumstances while maintaining its overarching aim of protecting public health through rigorous regulation of therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, allows the Secretary of the Department of Health to consent to the importation and supply of therapeutic goods that do not conform to certain requirements under the Therapeutic Goods Order 69, provided certain conditions are met. In this instance, the delegate of the Secretary has granted consent to Astellas Pharma Australia Pty Ltd for the importation and supply of tacrolimus products, which are used as immunosuppressants in organ transplantation, provided the labels still include the details of the previous sponsor (subsection 3(2)(l) of Therapeutic Goods Order 69). This consent is effective from 9 April 2015 to 31 March 2016. The consent is subject to conditions ensuring that the labels supplied are those currently in use, and that all correspondence is redirected to the current sponsor, Astellas Pharma Australia Pty Ltd. Importantly, no other changes have been made to the product itself. The obligations imposed by this consent on Astellas Pharma Australia Pty Ltd include ensuring that all labels for the specified tacrolimus products reflect the previous sponsor details as required, and that all correspondence related to the products is redirected to the current sponsor. This ensures continuity in the management and communication regarding these therapeutic goods. Additionally, Astellas Pharma must ensure that no other changes are made to the product, maintaining its integrity and compliance with therapeutic standards. Failure to comply with the conditions of this consent could result in legal repercussions. Under the Therapeutic Goods Act 1989, non-compliance could lead to enforcement actions, including fines or other penalties as prescribed by the Act. The maximum penalties for breaches related to therapeutic goods can include substantial fines and, in severe cases, imprisonment. These measures underscore the importance of adhering to the specified conditions to avoid legal consequences. Moreover, the Therapeutic Goods Administration (TGA) retains the authority to take additional regulatory actions if the consent conditions are breached, such as suspending or revoking the consent, or taking further enforcement actions against Astellas Pharma Australia Pty Ltd. Such actions are intended to protect public health and ensure that therapeutic goods available in the Australian market meet the necessary safety, quality, and efficacy standards. It is therefore crucial for Astellas Pharma to strictly adhere to the conditions set forth in the consent to avoid any potential penalties or regulatory actions.